$2.96
Live
Market Capitalization | 6.0M |
Book Value | $7.99 |
Earnings Per Share (EPS) | -47.88 |
Wall Street Target Price | 36.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.07% |
Return On Equity TTM | -15.28% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -20.9M |
Diluted Eps TTM | -47.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.8 |
EPS Estimate Next Year | -1.55 |
EPS Estimate Current Quarter | -2.43 |
EPS Estimate Next Quarter | -0.32 |
What analysts predicted
Upside of 1116.22%
Sell
Neutral
Buy
First Wave Biopharma Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Citadel Advisors Llc
Tower Research Capital LLC
UBS Group AG
azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.
Organization | First Wave Biopharma Inc |
Employees | 9 |
CEO | Mr. James R. Sapirstein M.B.A., R.Ph. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$2.96
+0.0%
Keyarch Acquisition Corp
$2.96
+0.0%
Connexa Sports Technologies Inc
$2.96
+0.0%
Us Value Etf
$2.96
+0.0%
Global X Msci Next Emerging
$2.96
+0.0%
Fat Projects Acquisition Corp
$2.96
+0.0%
Capital Link Global Fintech
$2.96
+0.0%
Applied Uv Inc
$2.96
+0.0%
Columbia International Esg Equity Income Etf
$2.96
+0.0%